NUE
50
2
FDX
39
-5
MO
57
-3
SRE
49
-5
DAL
80
3
BWA
42
-2
ALL
35
-3
SPG
48
-5
IR
55
-6
MRO
59
-3
PVH
57
2
HPE
53
3
CI
52
7
GIS
40
3
FOXA
53
8
TROW
48
8
EMN
52
-4
UNH
55
2
WAT
55
24
AON
47
-2
NUE
50
2
FDX
39
-5
MO
57
-3
SRE
49
-5
DAL
80
3
BWA
42
-2
ALL
35
-3
SPG
48
-5
IR
55
-6
MRO
59
-3
PVH
57
2
HPE
53
3
CI
52
7
GIS
40
3
FOXA
53
8
TROW
48
8
EMN
52
-4
UNH
55
2
WAT
55
24
AON
47
-2
Financhill
Back

InMed Pharmaceuticals 10K Form

Sell
27

INM
InMed Pharmaceuticals

Last Price:
0.24
Seasonality Move:
23.96%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive INM News And Ratings

See the #1 stock for the next 7 days that we like better than INM

INM Financial Statistics

Sales & Book Value

Annual Sales: $4.6M
Cash Flow: $-1.03M
Price / Cash Flow: 0
Annual Sales: $1.03
Price / Book: 0.35

Profitability

EPS (TTM): -1.32000
Net Income (TTM): $-7.68M
Gross Margin: $1.1M
Return on Equity: -70.1%
Return on Assets: -58.63%

InMed Pharmaceuticals Earnings Forecast

Key InMed Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 24 years for INM is 23.94%.
  • The Selling, General & Administrative Expenses for INM have been equal to 114.20% of Gross Profit Margin.
  • The Research & Development expenses have been 81.89% of Revenue.
  • The Interest Expense is -3.53% of Operating Income.
  • Per Share Earnings over the last 24 years have been positive in 16 years.

InMed Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: INM
Website: inmedpharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.41
Quick Ratio: 3.51

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

INM Technical Analysis vs Fundamental Analysis

Sell
27
InMed Pharmaceuticals (INM) is a Sell

Is InMed Pharmaceuticals a Buy or a Sell?